Update on Chronic Hepatitis C

Comprehensive Therapy

Volumn 29, Issue 4, 2003, Pages 224-232

  Ahmed, Aijaz ^a   Keeffe, Emmet B ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SEROTONIN UPTAKE INHIBITOR;

ANEMIA; CLINICAL TRIAL; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DRUG POTENTIATION; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; LIVER BIOPSY; NEUTROPENIA; PREVALENCE; RELAPSE; REVIEW; SERODIAGNOSIS; THROMBOCYTOPENIA; TREATMENT INDICATION;

ANTIVIRAL AGENTS; BIOPSY; DRUG THERAPY, COMBINATION; HEPATITIS C, CHRONIC; HUMANS; IMMUNOLOGIC TESTS; INTERFERON ALFA-2A; INTERFERON ALFA-2B; POLYETHYLENE GLYCOLS; RIBAVIRIN; TERMINOLOGY; TREATMENT OUTCOME;

EID: 0345743559     PISSN: 00988243     EISSN: None     Source Type: Journal    
DOI: 10.1385/COMP:29:4:224     Document Type: Review

References (45)

1. Yen T, Keeffe EB, Ahmed A. The epidemiology of hepatitis C virus infection. J Clin Gastroenterol. 2003;36:47-53.
2. Alter MJ, Kruszon-Moran D, Nainon OV, et al. The prevalence of hepatitis C virus infection in United States, 1998 through 1994. N Engl J Med. 1999;341:556-562.
3. Pradat P, Alberti A, Poynard T, et al. Predictive value of ALT levels for histologic findings in chronic hepatitis C: A European collaborative study. Hepatology. 2002;36:973-977.
4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med. 1999;340:1228-1233.
5. Seeff LB, Miller RN, Rabkin CS, et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med. 2000;132:105-111.
6. Liang TJ, Rehermann B, Seeff LB, et al. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000;132:296-305.
7. Choo Q-L, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359-361.
8. Simmonds P, Smith DB, McOmish F, et al. Identification of genotypes of hepatitis C virus by sequence comparisons in the core, El and NS-5 regions. J Gen Virology. 1994;75:1053-1061.
9. Pawlotsky JM. Molecular diagnosis of viral hepatitis. Gastroenterology. 2002;122:1554-1568.
10. Hoofnagle JH. National Institutes of Health Consensus Development Conference statement: Management of hepatitis C: 2002. Hepatology. 2002;36(Suppl 1):S3-S20.
11. National Institute of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997;26(Suppl 1):S2-S10.
12. Consensus Panel: EASL international consensus conference on hepatitis C: Paris, 26-28 February 1999. Consensus statement. J Hepatol. 1999;30:956-961.
13. Garcia-Tsao G, Boyer J. Outpatient liver biopsy: How safe is it? Ann Intern Med. 1993;118:150-153.
14. Wong JB, Bennett WG, Koff RS, et al. Pretreatment evaluation of chronic hepatitis C: Risks, benefits, and costs. JAMA. 1998;280:2088-2093.
15. Garcia G, Keeffe EB. Liver biopsy in chronic hepatitis C: Routine or selective [Editorial]. Am J Gastroenterol. 2001;96:3053-5.
16. Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable HCV RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy. Ann Intern Med. 1997;127:875-881.
17. Lau DT, Kleiner DE, Ghany MG, et al. 10-Year follow-up after interferon-α therapy for chronic hepatitis C. Hepatology. 1998;28:1121-1127.
18. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-982.
19. McHutchison JG, Manns M, Patel K, et al. International Hepatitis Interventional Therapy Group. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061-1069.
20. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet. 2001;358:958-965.
21. Zeuzem S, Feinman SV, Rasenack, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343:1666-1672.
22. Lindsay KL, Trepo C, Heintges T, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001;34:395-403.
23. Hadziyannis SJ, Cheinquer H, Morgan T, et al. Peginterferon alfa-2a (40 KD) (Pegasys) in combination with ribavirin (RBV): Efficacy and safety results from a phase III, randomized, double-blind, multicentre study examining effect of duration of treatment and RBV dose [Abstract]. J Hepatol. 2002;36:3.
24. Siebert U, Sroczynski G, Rossol S, et al. Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003;52:425-432.
25. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomised trials in the treatment of viral hepatitis: Effects of dose and duration. Hepatology. 1996;24:778-789.
26. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339:1485-1492.
27. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
28. Shiffman ML. Retreatment of patients with chronic hepatitis C. Hepatology. 2002;36(Suppl 1):S128-S134.
29. Cummings KJ, Lee SM, West ES, et al. Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: A meta-analysis of randomized trials. JAMA. 2001;285:193-199.
30. Herrine SK, Brown R, Esposito S, et al. Efficacy and safety of peginterferon alfa-2a (Pegasys) combination therapies in patients who relapsed on Rebetron therapy [Abstract]. Hepatology. 2002;36:358A.
31. Fried MW. Side effects of therapy of hepatitis C and their management. Hepatology. 2002;36(Suppl 1):S237-S244.
32. Musselman DL, Lawson DH, Gumnick JF, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001;344:961-966.
33. Dieterich DT, Pockros PJ, Schiff ER, et al. Epoetin alfa (Pro-crit) once weekly maintains ribavirin dose in hepatitis C virus (HCV)-infected patients treated with combination therapy: Interim results of a randomized, double-blind, placebo-controlled study. Hepatology. 2002;36:286A.
34. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345:1452-1457.
35. Schwimmer JB, Balistreri WF. Transmission, natural history, and treatment of hepatitis C virus infection in the pediatric population. Semin Liver Dis. 2000;20:37-46.
36. Shiffman ML, Stewart CA, Hofmann CM, et al. Chronic infection with hepatitis C virus in patients with elevated or persistently normal serum alanine aminotransferase levels: Comparison of hepatic histology and response to interferon therapy. J Infect Dis. 2000;182:1595-1601.
37. Bacon BR. Treatment of patients with hepatitis C and normal serum aminotransferese levels. Hepatology. 2002;36 (Suppl 1):S179-S184.
38. Sterling RK, Contos MJ, Sanyal AJ, et al. The clinical spectrum of hepatitis C virus in HIV coinfection. J Acquir Immune Defic Syndr. 2003;32:30-37.
39. Bica I, McGovern B, Dhar R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 2001;32:492-497.
40. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus co-infected patients. Hepatology. 1999;30:1054-1058.
41. Shakil AO, McGuire B, Crippin J, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology. 2002;36:1253-1258.
42. Nguyen MH, Keeffe EB. Screening for hepatocellular carcinoma. J Clin Gastroenterol. 2002;35:S86-S91.
43. Poynard T, Moussalli J, Ratziu V, et al. Effect of interferon therapy on the natural history of hepatitis C virus-related cirrhosis and hepatocellular carcinoma. Clin Liver Dis. 1999;3:869-881.
44. Keeffe EB. Vaccination against hepatitis A and B in chronic liver disease. Viral Hepatitis Rev. 1999;5:77-88.
45. Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881-886.